Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study

Gridelli, Cesare; Perrone, F.; Gallo, Ciro; Marinis, Filippo de; Ianniello, Giovanni Pietro; Cigolari, S.; Cariello, S.; Costanzo, Francesco Di; D’Aprile, Modesto; Rossi, Antonio; Migliorino, R.; Bartolucci, R.; Bianco, Andrea; M, Pergola; Monfardini, S.

doi:10.1016/s0959-8049(97)89011-9

Cited by 88 publications

(19 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the last decade, many phase II trials had suggested that single-agent chemotherapy with vinorelbine or gemcitabine was feasible and tolerable, and can improve survival and quality of life in elderly patients with advanced NSCLC [7,8,9,10]. In phase II trials of vinorelbine plus gemcitabine, response rates were between 18 and 35%, with a median survival time from 10 to 11 months.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, the risks of noncancerous comorbidities and poorer performance status (PS) also have an impact on the ability of the elderly to tolerate combination chemotherapy in this setting. Despite these concerns, several phase II trials have shown that single-agent vinorelbine or gemcitabine treatment and a non-platinum-containing combination of vinorelbine plus gemcitabine was well tolerated and showed activity in elderly patients aged ≥70 years with advanced NSCLC [7,8,9,10,11,12]. Several retrospective subset analyses of randomized trials have shown that main treatment outcome did not differ between adult and elderly patients treated with platinum-based combination chemotherapy [13,14,15].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic Factors in Elderly Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy

Chen

Dai

et al. 2009

Oncology

View full text Add to dashboard Cite

Objective: The prognosis of advanced non-small cell lung cancer (NSCLC) is poor. The aim of this study was to assess the outcome of chemotherapy for elderly patients with advanced NSCLC, focusing on the prognostic factors influencing survival. Methods: We reviewed retrospectively the medical records of 109 elderly patients with advanced NSCLC treated with chemotherapy from January 1999 to December 2006. Collected data included demographic information, clinical assessment before therapy, and information on treatment and outcome. Survival was estimated using the Kaplan-Meier method, and prognostic factors were analyzed by the log-rank test and Cox regression model. Results: The median survival time for the entire group was 10.5 (95% confidence interval: 9.15–11.88) months, with 1- and 2-year survival rates of 31.2 and 9.2%, respectively. Univariate analysis showed that performance status (PS; p = 0.013), comorbidity (p = 0.006), chemotherapy cycle (p = 0.006) and second-line therapy (p = 0.002) significantly influenced overall survival. In multivariate analysis, comorbidity, chemotherapy cycles and second-line therapy were identified as independent prognostic factors. Conclusions: Survival of elderly patients with advanced NSCLC treated with chemotherapy is significantly influenced by the patient’s PS, comorbidity, chemotherapy cycle and second-line therapy. These results may help to choose the appropriate treatment in clinical practice.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Prognostic Factors in Elderly Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy

Chen

Dai

et al. 2009

Oncology

View full text Add to dashboard Cite

show abstract

“…At the time this study was planned, single-drug efficacy of vinorelbine had been demonstrated (Gridelli et al, 1997) and the combination of carboplatin and vinorelbine was well tolerated in phase II trials (Masotti et al, 1995;Pronzato et al, 1996;Gridelli et al, 1998Gridelli et al, , 1999Santomaggio et al, 1998). Later vinorelbine/ cisplatin regimens have shown similar efficacy when compared to other cisplatin combinations with third-generation cytotoxic drugs (Schiller et al, 2002).…”

Section: Discussionmentioning

confidence: 99%

Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer

et al. 2006

View full text Add to dashboard Cite

This randomised multicentre trial was conducted to establish the optimal duration of palliative chemotherapy in advanced non-smallcell lung cancer (NSCLC). We compared a policy of three vs six courses of new-generation platinum-based combination chemotherapy with regard to effects on quality of life (QoL) and survival. Patients with stage IIIB or IV NSCLC and WHO performance status (PS) 0 -2 were randomised to receive three (C3) or six (C6) courses of carboplatin (area under the curve (AUC) 4, Chatelut's formula, equivalent to Calvert's AUC 5) on day 1 and vinorelbine 25 mg m À2 on days 1 and 8 of a 3-week cycle. Key end points were QoL at 18 weeks, measured with EORTC Quality of Life Questionnaire (QLQ)-C30 and QLQ-LC13, and overall survival. Secondary end points were progression-free survival and need of palliative radiotherapy. Two hundred and ninetyseven patients were randomised (C3 150, C6 147). Their median age was 65 years, 30% had PS 2 and 76% stage IV disease. Seventyeight and 54% of C3 and C6 patients, respectively, completed all scheduled chemotherapy courses. Compliance with QoL questionnaires was 88%. There were no significant group differences in global QoL, pain or fatigue up to 26 weeks. The dyspnoea palliation rate was lower in the C3 arm at 18 and 26 weeks (Po0.05), but this finding was inconsistent across different methods of analysis. Median survival in the C3 group was 28 vs 32 weeks in the C6 group (P ¼ 0.75, HR 1.04, 95% CI 0.82 -1.31). One-and 2-year survival rates were 25 and 9% vs 25 and 5% in the C3 and C6 arm, respectively. Median progression-free survival was 16 and 21 weeks in the C3 and C6 groups, respectively (P ¼ 0.21, HR 0.86, 95% CI 0.68 -1.08). In conclusion, palliative chemotherapy with carboplatin and vinorelbine beyond three courses conveys no survival or consistent QoL benefits in advanced NSCLC.

show abstract

“…The presence of cough, dyspnea, pain, hemoptysis, and anorexia was registered and graded from 0 -4 according to the scale devised by Hollen et al 17 and modified by Gridelli et al 9 The best subjective outcome for each patient was recorded.…”

Section: Methodsmentioning

confidence: 99%

Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin

Feliú

Gómez

Madroñal³

et al. 1999

Cancer

View full text Add to dashboard Cite

Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study

Cited by 88 publications

References 18 publications

Prognostic Factors in Elderly Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy

Prognostic Factors in Elderly Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy

Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer

Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin

Contact Info

Product

Resources

About